Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6418588 | 1.00 | CHRNA7 (0.57) | CHRNA7MAPK11MAPK14CNR2CYP3A4 | |
| SCHEMBL6418582 | 1.00 | CHRNA7 (0.57) | CHRNA7MAPK11MAPK14CNR2CYP3A4 | |
| SCHEMBL6412258 | 0.86 | CHRNA7 (0.57) | CHRNA7 | |
| SCHEMBL6417103 | 0.86 | CHRNA7 (0.63) | CHRNA7CNR2NPC1RAB9A | |
| SCHEMBL6414450 | 0.86 | CHRNA7 (0.57) | CHRNA7 | |
| SCHEMBL6412737 | 0.86 | CHRNA7 (0.63) | CHRNA7CNR2NPC1RAB9A | |
| SCHEMBL6414457 | 0.86 | CHRNA7 (0.57) | CHRNA7 | |
| SCHEMBL6417106 | 0.86 | CHRNA7 (0.63) | CHRNA7CNR2NPC1RAB9A | |
| SCHEMBL6413689 | 0.85 | CHRNA7 (0.59) | CHRNA7MAPK11MAPK14NPC1RAB9A | |
| SCHEMBL6410416 | 0.85 | CHRNA7 (0.59) | CHRNA7MAPK11MAPK14NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC | 2005-09-29 | — | — | US | claimed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC | 2005-09-29 | — | — | US | disclosed |
| US-6858613-B2 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | NAT1, CYP11B1, COASY | CHRNA7 1475/4885MAPK11 3442/4885MAPK14 3555/4885 |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | CHRNA7, UGT2B7, CHRNA5 | CHRNA7 1/4885MAPK11 3693/4885MAPK14 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.